PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries

European Journal of Pharmacology

Volumn 582, Issue 1-3, 2008, Pages 102-109

  Santos Silva, António José ^a   Cairrão, Elisa ^a,b   Morgado, Manuel ^a,b   Álvarez, Ezequiel ^a   Verde, Ignacio ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b Centro Hospitalar da Cova da Beira   (Portugal)

Author keywords

Cyclic nucleotide; Human umbilical artery; Phosphodiesterase; Smooth muscle

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; DIPYRIDAMOLE; FORSKOLIN; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HISTAMINE; ISOBUTYLMETHYLXANTHINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; ROLIPRAM; SEROTONIN;

ARTERY CONSTRICTION; ARTERY MUSCLE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECOND MESSENGER; UMBILICAL ARTERY; VASODILATATION;

1-METHYL-3-ISOBUTYLXANTHINE; ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIPYRIDAMOLE; FEMALE; FORSKOLIN; GUANYLATE CYCLASE; HISTAMINE; HUMANS; ISOENZYMES; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NAPHTHYRIDINES; NITROPRUSSIDE; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROLIPRAM; SEROTONIN; UMBILICAL ARTERIES; VASODILATOR AGENTS;

EID: 39149131022     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.12.017     Document Type: Article

References (31)

1. Amit A., Thaler I., Paz Y., and Itskovitz-Eldor J. The effect of a nitric oxide donor on Doppler flow velocity waveforms in the uterine artery during the first trimester of pregnancy. Ultrasound Obstet. Gynecol. 11 (1998) 94-98
2. Barnette M.S., Manning C.D., Price W.J., and Barone F.C. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle. J. Pharmacol. Exp. Ther. 264 (1993) 801-812
3. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
4. Downing J.W., Ramasubramanian R., Johnson R.F., Minzter B.H., Paschall R.L., Sundell H.W., Engelhardt B., and Lewis R. Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia. Med. Hypotheses 63 (2004) 1057-1064
5. 2 in human placental vessels from gestational diabetic pregnancies. Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H706-H713
6. Gupta R., Kumar G., and Kumar R.S. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity. Methods Find. Exp. Clin. Pharmacol. 27 (2005) 101-118
7. Hawley J., Rubin P.C., and Hill S.J. Distribution of receptors mediating phosphoinositide hydrolysis in cultured human umbilical artery smooth muscle and endothelial cells. Biochem. Pharmacol. 49 (1995) 1005-1011
8. Hetman J.M., Soderling S.H., Glavas N.A., and Beavo J.A. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 472-476
9. Kristek F., Koprdova R., and Cebova M. Long-term effects of early administered sildenafil and NO donor on the cardiovascular system of SHR. J. Physiol. Pharmacol. 58 (2007) 33-43
10. Leung S.W., Quan A., Lao T.T., and Man R.Y. Efficacy of different vasodilators on human umbilical arterial smooth muscle under normal and reduced oxygen conditions. Early Hum. Dev. 82 (2006) 457-462
11. Lillestll I.K., Helle K.B., and Aardal S. Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery. Scand. J. Clin. Lab. Invest. 58 (1998) 625-634
12. Lin C.S., Lin G., Xin Z.C., and Lue T.F. Expression, distribution and regulation of phosphodiesterase 5. Curr. Pharm. Des. 12 (2006) 3439-3457
13. Lovren F., Li X.F., Lytton J., and Triggle C. Functional characterization and m-RNA expression of 5-HT receptors mediating contraction in human umbilical artery. Br. J. Pharmacol. 127 (1999) 1247-1255
14. Lovren F., and Triggle C. Nitric oxide and sodium nitroprusside-induced relaxation of the human umbilical artery. Br. J. Pharmacol. 131 (2000) 521-529
15. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
16. Matsumoto T., Kobayashi T., and Kamata K. Phosphodiesterases in the vascular system. J. Smooth Muscle Res. 39 (2003) 67-86
17. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J., Raymond D.R., Elbatarny H.S., and Jimmo S.L. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 64 (2003) 533-546
18. Mochida H., Inoue H., Takagi M., Noto T., Yano K., and Kikkawa K. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Eur. J. Pharmacol. 440 (2002) 45-52
19. Mochida H., Takagi M., Inoue H., Noto T., Yano K., Fujishige K., Sasaki T., Yuasa K., Kotera J., Omori K., and Kikkawa K. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur. J. Pharmacol. 456 (2002) 91-98
20. Noguera M.A., Ivorra M.D., Lugnier C., and D'Ocon P. Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources. Naunyn Schmiedebergs Arch. Pharmacol. 363 (2001) 612-619
21. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ. Res. 100 (2007) 309-327
22. Pinheiro da Costa B.E., Scocco C., Poli de Figueiredo C.E., and Guimaraes J.A. Increased serum phosphodiesterase activity in women with pre-eclampsia. BJOG 113 (2006) 577-579
23. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266 (1994) L536-L543
24. Rubin L.J., Johnson L.R., Dodam J.R., Dhalla A.K., Magliola L., Laughlin M.H., and Jones A.W. Selective transport of adenosine into porcine coronary smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H1397-H1410
25. Rybalkin S.D., Bornfeldt K.E., Sonnenburg W.K., Rybalkina I.G., Kwak K.S., Hanson K., Krebs E.G., and Beavo J.A. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J. Clin. Invest. 100 (1997) 2611-2621
26. Rybalkin S.D., Yan C., Bornfeldt K.E., and Beavo J.A. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93 (2003) 280-291
27. Schneider A., Riess P., Elbers A., Neugebauer E., and Schaefer U. Polyclonal anti-histamine H2 receptor antibodies detect differential expression of H2 receptor protein in primary vascular cell types. Inflamm. Res. 53 (2004) 223-229
28. Segarra G., Medina P., Vila J.M., Martinez-Leon J.B., Domenech C., Prieto F., and Lluch S. Relaxation induced by milrinone and rolipram in human penile arteries and veins. Eur. J. Pharmacol. 444 (2002) 103-106
29. Tilley D.G., and Maurice D.H. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol. Pharmacol. 62 (2002) 497-506
30. Waldkirch E., Uckert S., Yildirim H., Sohn M., Jonas U., Stief C.G., Andersson K.E., and Hedlund P. Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries-immunohistochemical distribution and functional significance. World J. Urol. 23 (2005) 405-410
31. Willette R.N., Shiloh A.O., Sauermelch C.F., Sulpizio A., Michell M.P., Cieslinski L.B., Torphy T.J., and Ohlstein E.H. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. J. Cereb. Blood Flow Metab. 17 (1997) 210-219